Latest news and press releases about CeriBell, Inc. (CBLL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments.
Price
| Price | $24.50 |
| Market Cap | $930M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.26 |
| EV / EBITDA | -14.52 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -44.85% |
| Return on Invested Capital | -46.54% |
| Return on Assets | -39.67% |
| Gross Margin | 88.90% |
| Operating Margin | -68.62% |
| Net Margin | -64.73% |
Related companies: AUTL · BFLY · EHAB · KIDS · LAB · QSI · SMLR
Explore sector: Healthcare · Medical - Devices
More sections of CBLL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks